<!DOCTYPE html>
<!-- Generated by pkgdown: do not edit by hand --><html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<title> â€¢ RE-Test-Reports</title>
<script src="../deps/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<link href="../deps/bootstrap-5.3.1/bootstrap.min.css" rel="stylesheet">
<script src="../deps/bootstrap-5.3.1/bootstrap.bundle.min.js"></script><link href="../deps/font-awesome-6.5.2/css/all.min.css" rel="stylesheet">
<link href="../deps/font-awesome-6.5.2/css/v4-shims.min.css" rel="stylesheet">
<script src="../deps/headroom-0.11.0/headroom.min.js"></script><script src="../deps/headroom-0.11.0/jQuery.headroom.min.js"></script><script src="../deps/bootstrap-toc-1.0.1/bootstrap-toc.min.js"></script><script src="../deps/clipboard.js-2.0.11/clipboard.min.js"></script><script src="../deps/search-1.0.0/autocomplete.jquery.min.js"></script><script src="../deps/search-1.0.0/fuse.min.js"></script><script src="../deps/search-1.0.0/mark.min.js"></script><!-- pkgdown --><script src="../pkgdown.js"></script><meta property="og:title" content="">
</head>
<body>
    <a href="#main" class="visually-hidden-focusable">Skip to contents</a>


    <nav class="navbar navbar-expand-lg fixed-top bg-light" data-bs-theme="light" aria-label="Site navigation"><div class="container">

    <a class="navbar-brand me-2" href="../index.html">RE-Test-Reports</a>

    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">0.0.0.9000</small>


    <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
      <span class="navbar-toggler-icon"></span>
    </button>

    <div id="navbar" class="collapse navbar-collapse ms-3">
      <ul class="navbar-nav me-auto">
<li class="nav-item dropdown">
  <button class="nav-link dropdown-toggle" type="button" id="dropdown-reports" data-bs-toggle="dropdown" aria-expanded="false" aria-haspopup="true">Reports</button>
  <ul class="dropdown-menu" aria-labelledby="dropdown-reports">
<li><a class="dropdown-item" href="../articles/Aciclovir-Mean.html">Aciclovir-Mean</a></li>
    <li><a class="dropdown-item" href="../articles/Aciclovir-Mean-SVG.html">Aciclovir-Mean-SVG</a></li>
    <li><a class="dropdown-item" href="../articles/Aciclovir-Population.html">Aciclovir-Population</a></li>
    <li><a class="dropdown-item" href="../articles/Raltegravir-Absorption.html">Raltegravir-Absorption</a></li>
    <li><a class="dropdown-item" href="../articles/Raltegravir-Mass-Balance.html">Raltegravir-Mass-Balance</a></li>
    <li><a class="dropdown-item" href="../articles/Test-NO7.html">Test-NO7</a></li>
    <li><a class="dropdown-item" href="../articles/Test-NO8.html">Test-NO8</a></li>
    <li><a class="dropdown-item" href="../articles/Test-NO9.html">Test-NO9</a></li>
    <li><a class="dropdown-item" href="../articles/Test-NO10.html">Test-NO10</a></li>
    <li><a class="dropdown-item" href="../articles/Test-NO11.html">Test-NO11</a></li>
    <li><a class="dropdown-item" href="../articles/Test-NO12.html">Test-NO12</a></li>
  </ul>
</li>
<li class="active nav-item dropdown">
  <button class="nav-link dropdown-toggle" type="button" id="dropdown-qualification-reports" data-bs-toggle="dropdown" aria-expanded="false" aria-haspopup="true">Qualification Reports</button>
  <ul class="dropdown-menu" aria-labelledby="dropdown-qualification-reports">
<li><a class="dropdown-item" href="../articles/Qualification-CKD.html">Qualification-CKD</a></li>
    <li><a class="dropdown-item" href="../articles/Qualification-HI.html">Qualification-HI</a></li>
    <li><a class="dropdown-item" href="../articles/Pediatric_Qualification_Package_UGT1A1_Ontogeny.html">Pediatric_Qualification_Package_UGT1A1_Ontogeny</a></li>
    <li><a class="dropdown-item" href="../articles/Digoxin-Model.html">Digoxin-Model</a></li>
    <li><a class="dropdown-item" href="../articles/Propofol-Model.html">Propofol-Model</a></li>
    <li><a class="dropdown-item" href="../articles/dAb2-Model.html">dAb2-Model</a></li>
    <li><a class="dropdown-item" href="../articles/MEDI524YTE-Model.html">MEDI524YTE-Model</a></li>
    <li><a class="dropdown-item" href="../articles/MEDI524-Model.html">MEDI524-Model</a></li>
    <li><a class="dropdown-item" href="../articles/7E3-Model.html">7E3-Model</a></li>
    <li><a class="dropdown-item" href="../articles/CDA1-Model.html">CDA1-Model</a></li>
    <li><a class="dropdown-item" href="../articles/Inulin-Model.html">Inulin-Model</a></li>
    <li><a class="dropdown-item" href="../articles/BAY794620-Model.html">BAY794620-Model</a></li>
    <li><a class="dropdown-item" href="../articles/Tefibazumab-Model.html">Tefibazumab-Model</a></li>
    <li><a class="dropdown-item" href="../articles/TestInput01_DDI.html">TestInput01_DDI</a></li>
  </ul>
</li>
      </ul>
<ul class="navbar-nav">
<li class="nav-item"><form class="form-inline" role="search">
 <input class="form-control" type="search" name="search-input" id="search-input" autocomplete="off" aria-label="Search site" placeholder="Search for" data-search-index="../search.json">
</form></li>
      </ul>
</div>


  </div>
</nav><div class="container template-article">




<div class="row">
  <main id="main" class="col-md-9"><div class="page-header">

      <h1></h1>
            
      

      <div class="d-none name"><code>Digoxin-Model.Rmd</code></div>
    </div>

    
    
<div class="section level2">
<h2 id="building-and-evaluation-of-a-pbpk-model-for-digoxin-in-adults">Building and evaluation of a PBPK model for digoxin in adults<a class="anchor" aria-label="anchor" href="#building-and-evaluation-of-a-pbpk-model-for-digoxin-in-adults"></a>
</h2>
<table class="table">
<colgroup>
<col width="43%">
<col width="56%">
</colgroup>
<thead><tr class="header">
<th>Version</th>
<th>1.0-OSP11.0</th>
</tr></thead>
<tbody>
<tr class="odd">
<td>based on <em>Model Snapshot</em> and <em>Evaluation Plan</em>
</td>
<td><a href="https://github.com/Open-Systems-Pharmacology/Digoxin-Model/releases/tag/v1.0" class="external-link uri">https://github.com/Open-Systems-Pharmacology/Digoxin-Model/releases/tag/v1.0</a></td>
</tr>
<tr class="even">
<td>OSP Version</td>
<td>11.0</td>
</tr>
<tr class="odd">
<td>Qualification Framework Version</td>
<td>3.0</td>
</tr>
</tbody>
</table>
<p>This evaluation report and the corresponding PK-Sim project file are
filed at:</p>
<p><a href="https://github.com/Open-Systems-Pharmacology/OSP-PBPK-Model-Library/" class="external-link uri">https://github.com/Open-Systems-Pharmacology/OSP-PBPK-Model-Library/</a></p>
</div>
<div class="section level2">
<h2 id="table-of-contents">Table of Contents<a class="anchor" aria-label="anchor" href="#table-of-contents"></a>
</h2>
<ul>
<li><a href="#introduction">1 Introduction</a></li>
<li>
<a href="#methods">2 Methods</a>
<ul>
<li><a href="#modeling-strategy">2.1 Modeling strategy</a></li>
<li><a href="#data">2.2 Data</a></li>
<li><a href="#model-parameters-and-assumptions">2.3 Model parameters and
assumptions</a></li>
</ul>
</li>
<li>
<a href="#results-and-discussion">3 Results and Discussion</a>
<ul>
<li><a href="#final-input-parameters">3.1 Digoxin final input
parameters</a></li>
<li><a href="#diagnostics-plots">3.2 Digoxin Diagnostics Plots</a></li>
<li><a href="#ct-profiles-model-building">3.3 Digoxin Concentration-Time
profiles</a></li>
</ul>
</li>
<li><a href="#conclusion">4 Conclusion</a></li>
<li><a href="#references">5 References</a></li>
</ul>
</div>
<div class="section level2">
<h2 id="introduction">1 Introduction<a id="introduction"></a><a class="anchor" aria-label="anchor" href="#introduction"></a>
</h2>
<p>The presented model building and evaluation report evaluates the
performance of a PBPK model for digoxin in adults.</p>
<p>Digoxin is a cardiac glycoside used to treat atrial fibrillation,
atrial flutter and heart failure. Digoxin is transported by
P-glycoprotein 1 (P-gp), also known as multidrug resistance protein 1
(MDR1) or ATP-binding cassette sub-family B member 1 (ABCB1) or cluster
of differentiation 243 (CD243) poly-glycoprotein. P-gp and mainly
excreted unchanged via the kidneys with a small fraction eliminated via
biliary excretion and only a very low degree of hepatic metabolism (<a href="#References">Greiner 1999, Ochs 1978</a>). Many other substrates
of P-gp are metabolized by CYP3A4, setting digoxin apart as an exception
and thereby turning it into a model victim drug of P-gp-mediated
DDIs.</p>
<p>Digoxin is reported to have a large volume of distribution due to
extensive tissue binding and to be mainly excreted unchanged to urine
(50 - 70%) while the remainder of a dose is eliminated by hepatic
metabolism and biliary excretion (<a href="#References">Ochs 1978, Bauer
2008</a>)]. The final digoxin model applies target-binding, transport by
P-gp in various organs including gut, liver and kidney, an unspecific
hepatic metabolic clearance and glomerular filtration, and adequately
described the pharmacokinetics of digoxin in adults.</p>
<p>The digoxin model is a whole-body PBPK model, allowing for dynamic
translation between individuals. The digoxin report demonstrates the
level of confidence in the digoxin PBPK model with the OSP suite with
regard to reliable predictions of digoxin PK in adults during
model-informed drug development.</p>
</div>
<div class="section level2">
<h2 id="methods">2 Methods<a id="methods"></a><a class="anchor" aria-label="anchor" href="#methods"></a>
</h2>
<p>The PBPK model for digoxin in this report is based on the developed
and published digoxin PBPK model by Hanke <em>et al.</em> 2018. (<a href="#References">Hanke 2018</a>)</p>
<div class="section level3">
<h3 id="modeling-strategy">2.1 Modeling strategy<a id="modeling-strategy"></a><a class="anchor" aria-label="anchor" href="#modeling-strategy"></a>
</h3>
<p>The general concept of building a PBPK model has previously been
described by Kuepfer et al.Â (<a href="#References">Kuepfer 2016</a>).
Relevant information on anthropometric (height, weight) and
physiological parameters (e.g.Â blood flows, organ volumes, binding
protein concentrations, hematocrit, cardiac output) in adults was
gathered from the literature and has been previously published (<a href="#References">Schlender 2016</a>). The information was incorporated
into PK-SimÂ® and was used as default values for the simulations in
adults.</p>
<p>The applied activity and variability of plasma proteins and active
processes that are integrated into PK-SimÂ® are described in the publicly
available PK-SimÂ® Ontogeny Database Version 7.3 (<a href="#References">PK-Sim Ontogeny Database Version 7.3</a>) or
otherwise referenced for the specific process.</p>
<p>First, a base mean model was built using data from the single dose
escalation study to find an appropriate structure describing the PK of
digoxin. The mean PK model was developed using a typical European
individual. Unknown parameters were identified using the Parameter
Identification module provided in PK-SimÂ®. Structural model selection
was mainly guided by visual inspection of the resulting description of
data and biological plausibility.</p>
<p>Once the appropriate structural model was identified, additional
parameters for different formulations were identified, if available.</p>
<p>A final PBPK model was established and simulations were compared to
the reported data to evaluate model appropriateness and to assess model,
by means of diagnostics plots and predicted versus observed
concentration-time profiles, of which the results support an adequate
prediction of the PK in adults.</p>
<p>During model building, uncertainties in data quality, as well as
study differences may cause not being able to adequately describe the PK
of all reported clinical studies.</p>
</div>
<div class="section level3">
<h3 id="data">2.2 Data<a id="data"></a><a class="anchor" aria-label="anchor" href="#data"></a>
</h3>
<div class="section level4">
<h4 id="in-vitro-physico-chemical-data">2.2.1 In vitro / physico-chemical data<a class="anchor" aria-label="anchor" href="#in-vitro-physico-chemical-data"></a>
</h4>
<p>A literature search was performed to collect available information on
physicochemical properties of digoxin. The obtained information from the
literature is summarized in the table below, and is used for model
building.</p>
<table class="table">
<colgroup>
<col width="13%">
<col width="10%">
<col width="32%">
<col width="44%">
</colgroup>
<thead><tr class="header">
<th align="left"><strong>Parameter</strong></th>
<th><strong>Unit</strong></th>
<th><strong>Digoxin literature</strong></th>
<th><strong>Description</strong></th>
</tr></thead>
<tbody>
<tr class="odd">
<td align="left">MW</td>
<td>g/mol</td>
<td>780.93 (<a href="#References">Drugbank</a>)</td>
<td>Molecular weight</td>
</tr>
<tr class="even">
<td align="left">pKa</td>
<td></td>
<td>none</td>
<td>Acid dissociation constant</td>
</tr>
<tr class="odd">
<td align="left">Solubility (pH)</td>
<td>mg/L</td>
<td>64.8 (7) (<a href="#References">Drugbank</a>)</td>
<td>Solubility</td>
</tr>
<tr class="even">
<td align="left">logP</td>
<td></td>
<td>1.22, 1.62, 1.67 (<a href="#References">Alsenz 2007, Hinderling
1984, Atkinson 1988</a>)</td>
<td>Partition coefficient between octanol and water</td>
</tr>
<tr class="odd">
<td align="left">fu</td>
<td></td>
<td>70.0, 71.0, 77.7 (<a href="#References">Hinderling 1984, Obach 2008,
Neuhoff 2013</a>)</td>
<td>Fraction unbound</td>
</tr>
<tr class="even">
<td align="left">ATP1A2 KD</td>
<td>Âµmol/L</td>
<td>0.0256 (<a href="#References">Katz 2010</a>)</td>
<td>Dissociation constant</td>
</tr>
<tr class="odd">
<td align="left">ATP1A2 koff</td>
<td>1/min</td>
<td>n.a.</td>
<td>Dissociation rate constant</td>
</tr>
<tr class="even">
<td align="left">P-gp KM</td>
<td>Âµmol/L</td>
<td>73.0, 177.0 (<a href="#References">Collett 2004, Troutman
2003</a>)</td>
<td>Michaelis-Menten constant</td>
</tr>
<tr class="odd">
<td align="left">P-gp kcat</td>
<td>1/min</td>
<td>n.a.</td>
<td>P-gp catalytic rate constant</td>
</tr>
<tr class="even">
<td align="left">CLhep</td>
<td>mL/min</td>
<td>n.a.</td>
<td>Hepatic plasma clearance</td>
</tr>
<tr class="odd">
<td align="left">GFR fraction</td>
<td>1/min</td>
<td>1</td>
<td>Fraction of filtered drug reaching the urine</td>
</tr>
<tr class="even">
<td align="left">Formulation</td>
<td></td>
<td>solution</td>
<td>Formulation used in predictions</td>
</tr>
<tr class="odd">
<td align="left">Cell permeabilities</td>
<td></td>
<td>PK-Sim</td>
<td>Permeation across cell membranes</td>
</tr>
<tr class="even">
<td align="left">Partition coefficients</td>
<td></td>
<td>Rodgers &amp; Rowland</td>
<td>Organ-plasma partition coefficients</td>
</tr>
<tr class="odd">
<td align="left">Specific intest. perm.</td>
<td>dm/min</td>
<td>n.a.</td>
<td>Normalized to surface area</td>
</tr>
<tr class="even">
<td align="left">Specific organ perm.</td>
<td>dm/min</td>
<td>n.a.</td>
<td>Normalized to surface area</td>
</tr>
</tbody>
</table>
<ul>
<li>ATP1A2: ATPase Na+/K+ transporting subunit alpha 2, CL: clearance,
GFR: glomerular filtration rate, intest.: intestinal, n.a.: not
available, perm.: permeability, P-gp: Pglycoprotein, PK-Sim: PK-Sim
Standard calculation method, R + R: Rodgers and Rowland calculation
method</li>
</ul>
</div>
<div class="section level4">
<h4 id="clinical-data">2.2.2 Clinical data<a class="anchor" aria-label="anchor" href="#clinical-data"></a>
</h4>
<p>A literature search was performed to collect available clinical data
on digoxin in adults.</p>
<p>The following publications were found in adults for model building
and evaluation:</p>
<table class="table">
<colgroup>
<col width="36%">
<col width="63%">
</colgroup>
<thead><tr class="header">
<th>Publication</th>
<th>Study description</th>
</tr></thead>
<tbody>
<tr class="odd">
<td><a href="#References">Becquemont 2001</a></td>
<td>Becquemont, L. et al.Â Effect of grapefruit juice on digoxin
pharmacokinetics in humans. Clin. Pharmacol. Ther. 70, 311â€“6
(2001).</td>
</tr>
<tr class="even">
<td><a href="#References">Ding 2004</a></td>
<td>Ding, R. et al.Â Substantial pharmacokinetic interaction between
digoxin and ritonavir in healthy volunteers. Clin. Pharmacol. Ther. 76,
73â€“84 (2004).</td>
</tr>
<tr class="odd">
<td><a href="#References">Eckermann 2012</a></td>
<td>Eckermann, G., Lahu, G., Nassr, N. &amp; Bethke, T.D. Absence of
pharmacokinetic interaction between roflumilast and digoxin in healthy
adults. J. Clin. Pharmacol. 52, 251â€“7 (2012).</td>
</tr>
<tr class="even">
<td><a href="#References">Friedrich 2011</a></td>
<td>Friedrich, C. et al.Â Evaluation of the pharmacokinetic interaction
after multiple oral doses of linagliptin and digoxin in healthy
volunteers. Eur. J. Drug Metab. Pharmacokinet. 36, 17â€“24 (2011).</td>
</tr>
<tr class="odd">
<td><a href="#References">Greiner 1999</a></td>
<td>Greiner, B. et al.Â The role of intestinal P-glycoprotein in the
interaction of digoxin and rifampin. J. Clin. Invest. 104, 147â€“53
(1999).</td>
</tr>
<tr class="even">
<td><a href="#References">Gurley 2008b</a></td>
<td>Gurley, B.J., Swain, A., Williams, D.K., Barone, G. &amp; Battu,
S.K. Gauging the clinical significance of P-glycoprotein-mediated
herb-drug interactions: comparative effects of St.Â Johnâ€™s wort,
Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics.
Mol. Nutr. food Res. 52, 772â€“9 (2008).</td>
</tr>
<tr class="odd">
<td><a href="#References">Hayward 1978</a></td>
<td>Hayward, R.P., Greenwood, H. &amp; Hamer, J. Comparison of digoxin
and medigoxin in normal subjects. Br. J. Clin. Pharmacol. 6, 81â€“6
(1978).</td>
</tr>
<tr class="even">
<td><a href="#References">Jalava 1997</a></td>
<td>Jalava, K.M., Partanen, J. &amp; Neuvonen, P.J. Itraconazole
decreases renal clearance of digoxin. Ther. Drug Monit. 19, 609â€“13
(1997).</td>
</tr>
<tr class="odd">
<td><a href="#References">Johne 1999</a></td>
<td>Johne, A. et al.Â Pharmacokinetic interaction of digoxin with an
herbal extract from St Johnâ€™s wort (Hypericum perforatum). Clin.
Pharmacol. Ther. 66, 338â€“45 (1999).</td>
</tr>
<tr class="even">
<td><a href="#References">Kirby 2012</a></td>
<td>Kirby B.J., Collier A.C., Kharasch E.D., Whittington D., Thummel
K.E., Unadkat J.D. Complex drug interactions of the HIV protease
inhibitors 3: effect of simultaneous or staggered dosing of digoxin and
ritonavir, nelfinavir, rifampin, or bupropion. Drug Metab Dispos. 2012
Mar;40(3):610-6.</td>
</tr>
<tr class="odd">
<td><a href="#References">Kirch 1986</a></td>
<td>Kirch, W., Hutt, H.J., Dylewicz, P., GrÃ¤f, K.J. &amp; Ohnhaus, E.E.
Dose-dependence of the nifedipine-digoxin interaction? Clin. Pharmacol.
Ther. 39, 35â€“9 (1986).</td>
</tr>
<tr class="even">
<td><a href="#References">Koup 1975</a></td>
<td>Koup, J.R., Greenblatt, D.J., Jusko, W.J., Smith, T.W. &amp;
Koch-Weser, J. Pharmacokinetics of digoxin in normal subjects after
intravenous bolus and infusion doses. J. Pharmacokinet. Biopharm. 3,
181â€“92 (1975).</td>
</tr>
<tr class="odd">
<td><a href="#References">Kramer 1979</a></td>
<td>Kramer, W.G. et al.Â Pharmacokinetics of digoxin: relationship
between response intensity and predicted compartmental drug levels in
man. J. Pharmacokinet. Biopharm. 7, 47â€“61 (1979).</td>
</tr>
<tr class="even">
<td><a href="#References">Lalonde 1985</a></td>
<td>Lalonde, R.L., Deshpande, R., Hamilton, P.P., McLean, W.M. &amp;
Greenway, D.C. Acceleration of digoxin clearance by activated charcoal.
Clin. Pharmacol. Ther. 37, 367â€“71 (1985).</td>
</tr>
<tr class="odd">
<td><a href="#References">Larsen 2007</a></td>
<td>Larsen, U.L. et al.Â Human intestinal P-glycoprotein activity
estimated by the model substrate digoxin. Scand. J. Clin. Lab. Invest.
67, 123â€“34 (2007).</td>
</tr>
<tr class="even">
<td><a href="#References">Martin 1997</a></td>
<td>Martin, D.E. et al.Â Lack of effect of eprosartan on the single dose
pharmacokinetics of orally administered digoxin in healthy male
volunteers. Br. J. Clin. Pharmacol. 43, 661â€“4 (1997).</td>
</tr>
<tr class="odd">
<td><a href="#References">Ochs 1975</a></td>
<td>Ochs, H., Bodem, G., SchÃ¤fer, P.K., Kodrat, G., Dengler, H.J.
Absorption of digoxin from the distal parts of the intestine in man. Eur
J Clin Pharmacol. 1975 Dec 19;9(2-3):95-7.</td>
</tr>
<tr class="even">
<td><a href="#References">Ochs 1978</a></td>
<td>Ochs, H., Greenblatt, D.J., Bodem, G. &amp; Harmatz, J.S.
Dose-independent pharmacokinetics of digoxin in humans. Am. Heart J. 96,
507â€“11 (1978).</td>
</tr>
<tr class="odd">
<td><a href="#References">Oosterhuis 1991</a></td>
<td>Oosterhuis, B., Jonkman, J.H., Andersson, T., Zuiderwijk, P.B. &amp;
Jedema, J.N. Minor effect of multiple dose omeprazole on the
pharmacokinetics of digoxin after a single oral dose. Br. J. Clin.
Pharmacol. 32, 569â€“72 (1991).</td>
</tr>
<tr class="even">
<td><a href="#References">Qiu 2010</a></td>
<td>Qiu, R. et al.Â Lack of a pharmacokinetic interaction between dimebon
(latrepirdine) and digoxin in healthy subjects. Am. Soc. Clin.
Pharmacol. Ther. Meet. Atlanta, GA, USA (2010).</td>
</tr>
<tr class="odd">
<td><a href="#References">Ragueneau 1999</a></td>
<td>Ragueneau, I. et al.Â Pharmacokinetic and pharmacodynamic drug
interactions between digoxin and macrogol 4000, a laxative polymer, in
healthy volunteers. Br. J. Clin. Pharmacol. 48, 453â€“6 (1999).</td>
</tr>
<tr class="even">
<td><a href="#References">Rengelshausen 2003</a></td>
<td>Rengelshausen, J. et al.Â Contribution of increased oral
bioavailability and reduced nonglomerular renal clearance of digoxin to
the digoxin-clarithromycin interaction. Br. J. Clin. Pharmacol. 56, 32â€“8
(2003).</td>
</tr>
<tr class="odd">
<td><a href="#References">Rodin 1988</a></td>
<td>Rodin, S.M., Johnson, B.F., Wilson, J., Ritchie, P. &amp; Johnson,
J. Comparative effects of verapamil and isradipine on steady-state
digoxin kinetics. Clin. Pharmacol. Ther. 43, 668â€“72 (1988).</td>
</tr>
<tr class="even">
<td><a href="#References">Steiness 1982</a></td>
<td>Steiness, E., Waldorff, S. &amp; Hansen, P.B. Renal digoxin
clearance: dependence on plasma digoxin and diuresis. Eur. J. Clin.
Pharmacol. 23, 151â€“4 (1982).</td>
</tr>
<tr class="odd">
<td><a href="#References">Tayrouz 2003</a></td>
<td>Tayrouz, Y. et al.Â Pharmacokinetic and pharmaceutic interaction
between digoxin and Cremophor RH40. Clin. Pharmacol. Ther. 73, 397â€“405
(2003).</td>
</tr>
<tr class="even">
<td><a href="#References">Tsutsumi 2002</a></td>
<td>Tsutsumi, K. et al.Â The effect of erythromycin and clarithromycin on
the pharmacokinetics of intravenous digoxin in healthy volunteers. J.
Clin. Pharmacol. 42, 1159â€“64 (2002).</td>
</tr>
<tr class="odd">
<td><a href="#References">Vaidyanathan 2008</a></td>
<td>Vaidyanathan, S. et al.Â Pharmacokinetics of the oral direct renin
inhibitor aliskiren in combination with digoxin, atorvastatin, and
ketoconazole in healthy subjects: the role of P-glycoprotein in the
disposition of aliskiren. J. Clin. Pharmacol. 48, 1323â€“38 (2008).</td>
</tr>
<tr class="even">
<td><a href="#References">Verstuyft 2003</a></td>
<td>Verstuyft, C. et al.Â Dipyridamole enhances digoxin bioavailability
via P-glycoprotein inhibition. Clin. Pharmacol. Ther. 73, 51â€“60
(2003).</td>
</tr>
<tr class="odd">
<td><a href="#References">Wagner 1981</a></td>
<td>Wagner, J.G., Popat, K.D., Das, S.K., Sakmar, E. &amp; Movahhed, H.
Evidence of nonlinearity in digoxin pharmacokinetics. J. Pharmacokinet.
Biopharm. 9, 147â€“66 (1981).</td>
</tr>
<tr class="even">
<td><a href="#References">Westphal 2000</a></td>
<td>Westphal, K. et al.Â Oral bioavailability of digoxin is enhanced by
talinolol: evidence for involvement of intestinal P-glycoprotein. Clin.
Pharmacol. Ther. 68, 6â€“12 (2000).</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="section level3">
<h3 id="model-parameters-and-assumptions">2.3 Model parameters and
assumptions<a id="model-parameters-and-assumptions"></a><a class="anchor" aria-label="anchor" href="#model-parameters-and-assumptions"></a>
</h3>
<div class="section level4">
<h4 id="absorption">2.3.1 Absorption<a class="anchor" aria-label="anchor" href="#absorption"></a>
</h4>
<p>For oral administration of digoxin, the following parameters, amongst
others, play a role with regards to the absorption kinetics of a
compound, which can be estimated with PBPK: solubility, lipophilicity
and intestinal permeability. To accurately predict the digoxin plasma
concentrations following intravenous and oral administration, the
relative expression of P-gp in the intestinal mucosa was increased
(3.57-fold) compared to the PK-Sim database RT-PCR expression profile
(see table below). This factor has been identified in an optimization
that included digoxin plasma concentrations and fraction excreted to
urine data following intravenous and oral administration plus digoxin
excreted to duodenum measurements after intravenous administration <a href="#References">Caldwell 1976</a>. The optimized P-gp expression
profile shows highest expression in small intestinal mucosa (1.41
Âµmol/L), followed by kidney (1.00 Âµmol/L), large intestinal mucosa (0.56
Âµmol/L), liver (0.27 Âµmol/L) and tissues of lower expression.
Implementation of transport by OATP (4C1) did not improve the model
performance and was not used in the final model.</p>
<table class="table">
<colgroup>
<col width="10%">
<col width="7%">
<col width="25%">
<col width="34%">
<col width="10%">
<col width="10%">
</colgroup>
<thead><tr class="header">
<th align="left"><strong>Protein</strong></th>
<th><strong>Mean reference concentration [Âµmol protein/L in the tissue
of highest expression]</strong></th>
<th><strong>Geometric standard deviation of reference
concentration</strong></th>
<th><strong>Relative expression in the different organs (PK-Sim
expression database profile)</strong></th>
<th>Half-life liver [h]</th>
<th>Half-life intestine [h]</th>
</tr></thead>
<tbody><tr class="odd">
<td align="left">P-gp (efflux)</td>
<td>1.41 optimized</td>
<td>1.60 (<a href="#References">Prasad 2014</a>)</td>
<td>RT-PCR, with the relative expression in intestinal mucosa increased
by a factor of 3.57 (optimized)(<a href="#References">Nishimura
2005</a>)</td>
<td>36</td>
<td>23</td>
</tr></tbody>
</table>
</div>
<div class="section level4">
<h4 id="distribution">2.3.2 Distribution<a class="anchor" aria-label="anchor" href="#distribution"></a>
</h4>
<p>Digoxin is reported to have a large volume of distribution due to
extensive tissue binding and to be mainly excreted unchanged to urine
(50 - 70%) while the remainder of a dose is eliminated by hepatic
metabolism and biliary excretion (<a href="#References">Ochs 1978, Bauer
2008</a>). Implementation of target-binding to the ATPase Na+/K+
transporting subunit alpha 2 (ATP1A2) was crucial, to mechanistically
describe the large volume of distribution and the long plasma half-life
of digoxin.</p>
<p>It has reported that the fraction unbound of digoxin ranges from 70
to 77.9% (<a href="#References">Hinderling 1984, Obach 2008, Neuhoff
2013</a>).</p>
<p>After testing the available organ-plasma partition coefficient and
cell permeability calculation methods built in PK-Sim, observed clinical
data was best described by choosing the partition coefficient
calculation method by Rodgers and Rowland, and PK-Sim standard cell
permeability calculation method. Specific organ permeability normalized
to surface area was automatically calculated by PK-Sim.</p>
</div>
<div class="section level4">
<h4 id="metabolism-and-elimination">2.3.3 Metabolism and Elimination<a class="anchor" aria-label="anchor" href="#metabolism-and-elimination"></a>
</h4>
<p>The final digoxin model applies target-binding to the ATP1A2,
transport by P-gp in various organs including gut, liver and kidney, an
unspecific hepatic metabolic clearance and glomerular filtration.</p>
</div>
</div>
</div>
<div class="section level2">
<h2 id="results-and-discussion">3 Results and Discussion<a id="results-and-discussion"></a><a class="anchor" aria-label="anchor" href="#results-and-discussion"></a>
</h2>
<p>The PBPK model for digoxin was developed with clinical
pharmacokinetic data covering intravenous as well as oral administration
with a dose range of 0.125 to 1.5 mg including single dose and multiple
dose clinical data, for different types of tablet formulations.</p>
<p>During the model-fitting, the following parameters were estimated
(all other parameters were fixed to reported values):</p>
<ul>
<li>Lipophilicity</li>
<li>ATP1A2 Dissociation constant (Kd)</li>
<li>P-gp catalytic rate constant (Kcat)</li>
<li>Hepatic Clearance (CLhep)</li>
<li>Specific intestinal permeability (transcellular)</li>
<li>Specific organ permeability</li>
</ul>
<p>The fit resulted in an adequate description of the clinical data.
Additional implementation of transport by OATP (4C1) did not improve the
model performance and was not used in the final model.</p>
<div class="section level3">
<h3 id="digoxin-final-input-parameters">3.1 Digoxin final input
parameters<a id="final-input-parameters"></a><a class="anchor" aria-label="anchor" href="#digoxin-final-input-parameters"></a>
</h3>
<p>The compound parameter values of the final digoxin PBPK model are
illustrated below.</p>
<div class="section level4">
<h4 id="compound-digoxin">Compound: Digoxin<a class="anchor" aria-label="anchor" href="#compound-digoxin"></a>
</h4>
<div class="section level5">
<h5 id="parameters">Parameters<a class="anchor" aria-label="anchor" href="#parameters"></a>
</h5>
<table class="table">
<colgroup>
<col width="33%">
<col width="14%">
<col width="34%">
<col width="12%">
<col width="4%">
</colgroup>
<thead><tr class="header">
<th>Name</th>
<th>Value</th>
<th>Value Origin</th>
<th>Alternative</th>
<th>Default</th>
</tr></thead>
<tbody>
<tr class="odd">
<td>Solubility at reference pH</td>
<td>64.8 mg/l</td>
<td>Internet-In Vitro-Drugbank</td>
<td>Aqueous Solubility</td>
<td>True</td>
</tr>
<tr class="even">
<td>Reference pH</td>
<td>7</td>
<td>Internet-In Vitro-Drugbank</td>
<td>Aqueous Solubility</td>
<td>True</td>
</tr>
<tr class="odd">
<td>Lipophilicity</td>
<td>1.40017663 Log Units</td>
<td>Parameter Identification-Parameter Identification</td>
<td>fitted</td>
<td>True</td>
</tr>
<tr class="even">
<td>Fraction unbound (plasma, reference value)</td>
<td>0.71</td>
<td>Publication-In Vitro-Neuhoff 2013</td>
<td>Neuhoff (2013)</td>
<td>True</td>
</tr>
<tr class="odd">
<td>Permeability</td>
<td>1.0115E-05 dm/min</td>
<td></td>
<td>fitted</td>
<td>True</td>
</tr>
<tr class="even">
<td>Specific intestinal permeability (transcellular)</td>
<td>2.7627E-07 dm/min</td>
<td></td>
<td>fitted</td>
<td>True</td>
</tr>
<tr class="odd">
<td>Is small molecule</td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td>Molecular weight</td>
<td>780.93 g/mol</td>
<td>Internet-In Vitro-Drugbank</td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td>Plasma protein binding partner</td>
<td>Albumin</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</div>
<div class="section level5">
<h5 id="calculation-methods">Calculation methods<a class="anchor" aria-label="anchor" href="#calculation-methods"></a>
</h5>
<table class="table">
<thead><tr class="header">
<th>Name</th>
<th>Value</th>
</tr></thead>
<tbody>
<tr class="odd">
<td>Partition coefficients</td>
<td>Rodgers and Rowland</td>
</tr>
<tr class="even">
<td>Cellular permeabilities</td>
<td>PK-Sim Standard</td>
</tr>
</tbody>
</table>
</div>
<div class="section level5">
<h5 id="processes">Processes<a class="anchor" aria-label="anchor" href="#processes"></a>
</h5>
<div class="section level6">
<h6 id="specific-binding-atp1a2-katz-2010">Specific Binding: ATP1A2-Katz (2010)<a class="anchor" aria-label="anchor" href="#specific-binding-atp1a2-katz-2010"></a>
</h6>
<p>Molecule: ATP1A2</p>
<div class="section level7">
<h6 id="parameters-1">Parameters<a class="anchor" aria-label="anchor" href="#parameters-1"></a>
</h6>
<table class="table">
<thead><tr class="header">
<th>Name</th>
<th>Value</th>
<th>Value Origin</th>
</tr></thead>
<tbody>
<tr class="odd">
<td>koff</td>
<td>0.00098888 1/min</td>
<td>Publication-In Vitro-Katz 2010</td>
</tr>
<tr class="even">
<td>Kd</td>
<td>25.6 nmol/l</td>
<td>Parameter Identification</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="section level6">
<h6 id="systemic-process-total-hepatic-clearance-fitted">Systemic Process: Total Hepatic Clearance-Fitted<a class="anchor" aria-label="anchor" href="#systemic-process-total-hepatic-clearance-fitted"></a>
</h6>
<p>Species: Human</p>
<div class="section level7">
<h6 id="parameters-2">Parameters<a class="anchor" aria-label="anchor" href="#parameters-2"></a>
</h6>
<table class="table">
<colgroup>
<col width="39%">
<col width="27%">
<col width="32%">
</colgroup>
<thead><tr class="header">
<th>Name</th>
<th>Value</th>
<th>Value Origin</th>
</tr></thead>
<tbody>
<tr class="odd">
<td>Fraction unbound (experiment)</td>
<td>0.71</td>
<td></td>
</tr>
<tr class="even">
<td>Lipophilicity (experiment)</td>
<td>1.40017663 Log Units</td>
<td></td>
</tr>
<tr class="odd">
<td>Plasma clearance</td>
<td>0 ml/min/kg</td>
<td></td>
</tr>
<tr class="even">
<td>Specific clearance</td>
<td>0.03758077 1/min</td>
<td>Parameter Identification</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="section level6">
<h6 id="transport-protein-p-gp-stephens-2001">Transport Protein: P-gp-Stephens (2001)<a class="anchor" aria-label="anchor" href="#transport-protein-p-gp-stephens-2001"></a>
</h6>
<p>Molecule: P-gp</p>
<div class="section level7">
<h6 id="parameters-3">Parameters<a class="anchor" aria-label="anchor" href="#parameters-3"></a>
</h6>
<table class="table">
<thead><tr class="header">
<th>Name</th>
<th>Value</th>
<th>Value Origin</th>
</tr></thead>
<tbody>
<tr class="odd">
<td>Transporter concentration</td>
<td>1 Âµmol/l</td>
<td></td>
</tr>
<tr class="even">
<td>Vmax</td>
<td>8.67 Âµmol/l/min</td>
<td></td>
</tr>
<tr class="odd">
<td>Km</td>
<td>177 Âµmol/l</td>
<td></td>
</tr>
<tr class="even">
<td>kcat</td>
<td>71.163 1/min</td>
<td>Parameter Identification</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="section level6">
<h6 id="systemic-process-glomerular-filtration-steiness-1982">Systemic Process: Glomerular Filtration-Steiness (1982)<a class="anchor" aria-label="anchor" href="#systemic-process-glomerular-filtration-steiness-1982"></a>
</h6>
<p>Species: Human</p>
<div class="section level7">
<h6 id="parameters-4">Parameters<a class="anchor" aria-label="anchor" href="#parameters-4"></a>
</h6>
<table class="table">
<thead><tr class="header">
<th>Name</th>
<th align="right">Value</th>
<th>Value Origin</th>
</tr></thead>
<tbody><tr class="odd">
<td>GFR fraction</td>
<td align="right">1</td>
<td>Publication-Steiness (1982)</td>
</tr></tbody>
</table>
</div>
</div>
</div>
</div>
</div>
<div class="section level3">
<h3 id="digoxin-diagnostics-plots">3.2 Digoxin Diagnostics Plots<a id="diagnostics-plots"></a><a class="anchor" aria-label="anchor" href="#digoxin-diagnostics-plots"></a>
</h3>
<p>Below you find the goodness-of-fit visual diagnostic plots for
digoxin PBPK model performance (observed versus individually simulated
plasma concentration and weighted residuals versus time, including the
geometric mean fold error (GMFE)) of all data used for model
building.</p>
<p><a id="table-3-1"></a></p>
<p><strong>Table 3-1: GMFE for Goodness of fit plot for concentration in
plasma.</strong></p>
<table class="table">
<thead><tr class="header">
<th align="left">Group</th>
<th align="left">GMFE</th>
</tr></thead>
<tbody>
<tr class="odd">
<td align="left">Digoxin colonic admin.</td>
<td align="left">2.13</td>
</tr>
<tr class="even">
<td align="left">Digoxin iv</td>
<td align="left">1.45</td>
</tr>
<tr class="odd">
<td align="left">Digoxin po SD</td>
<td align="left">1.30</td>
</tr>
<tr class="even">
<td align="left">Digoxin po, MD</td>
<td align="left">1.64</td>
</tr>
<tr class="odd">
<td align="left">All</td>
<td align="left">1.46</td>
</tr>
</tbody>
</table>
<p><br><br></p>
<p><a id="figure-3-1"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F008_section_diagnostics-plots%2F2_gof_plot_predictedVsObserved.png"></p>
<p><strong>Figure 3-1: Goodness of fit plot for concentration in
plasma.</strong></p>
<p><br><br></p>
<p><a id="figure-3-2"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F008_section_diagnostics-plots%2F3_gof_plot_residualsOverTime.png"></p>
<p><strong>Figure 3-2: Goodness of fit plot for concentration in
plasma.</strong></p>
<p><br><br></p>
</div>
<div class="section level3">
<h3 id="digoxin-concentration-time-profiles">3.3 Digoxin Concentration-Time
profiles<a id="ct-profiles-model-building"></a><a class="anchor" aria-label="anchor" href="#digoxin-concentration-time-profiles"></a>
</h3>
<p>Simulated versus observed plasma concentration-time profiles of all
data are listed below.</p>
<p><a id="figure-3-3"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F1_time_profile_plot_Digoxin_Digoxin_colon__0_5_mg.png"></p>
<p><strong>Figure 3-3: Time Profile Analysis 1</strong></p>
<p><br><br></p>
<p><a id="figure-3-4"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F2_time_profile_plot_Digoxin_Digoxin_colon__0_5_mg.png"></p>
<p><strong>Figure 3-4: Time Profile Analysis</strong></p>
<p><br><br></p>
<p><a id="figure-3-5"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F3_time_profile_plot_Digoxin_Digoxin_iv__0_01_mg_kg.png"></p>
<p><strong>Figure 3-5: Time Profile Analysis</strong></p>
<p><br><br></p>
<p><a id="figure-3-6"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F4_time_profile_plot_Digoxin_Digoxin_iv__0_01_mg_kg.png"></p>
<p><strong>Figure 3-6: Time Profile Analysis 1</strong></p>
<p><br><br></p>
<p><a id="figure-3-7"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F5_time_profile_plot_Digoxin_Digoxin_iv__0_01_mg_kg__Charcoal.png"></p>
<p><strong>Figure 3-7: Time Profile Analysis</strong></p>
<p><br><br></p>
<p><a id="figure-3-8"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F6_time_profile_plot_Digoxin_Digoxin_iv__0_01_mg_kg__Charcoal.png"></p>
<p><strong>Figure 3-8: Time Profile Analysis 1</strong></p>
<p><br><br></p>
<p><a id="figure-3-9"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F7_time_profile_plot_Digoxin_Digoxin_iv__0_5_mg__1_h.png"></p>
<p><strong>Figure 3-9: Time Profile Analysis</strong></p>
<p><br><br></p>
<p><a id="figure-3-10"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F8_time_profile_plot_Digoxin_Digoxin_iv__0_5_mg__1_h.png"></p>
<p><strong>Figure 3-10: Time Profile Analysis 1</strong></p>
<p><br><br></p>
<p><a id="figure-3-11"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F9_time_profile_plot_Digoxin_Digoxin_iv__0_5_mg__3_h.png"></p>
<p><strong>Figure 3-11: Time Profile Analysis</strong></p>
<p><br><br></p>
<p><a id="figure-3-12"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F10_time_profile_plot_Digoxin_Digoxin_iv__0_5_mg__3_h.png"></p>
<p><strong>Figure 3-12: Time Profile Analysis 1</strong></p>
<p><br><br></p>
<p><a id="figure-3-13"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F11_time_profile_plot_Digoxin_Digoxin_iv__0_5_mg__Bolus.png"></p>
<p><strong>Figure 3-13: Time Profile Analysis</strong></p>
<p><br><br></p>
<p><a id="figure-3-14"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F12_time_profile_plot_Digoxin_Digoxin_iv__0_5_mg__Bolus.png"></p>
<p><strong>Figure 3-14: Time Profile Analysis 1</strong></p>
<p><br><br></p>
<p><a id="figure-3-15"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F13_time_profile_plot_Digoxin_Digoxin_iv__0_75_mg__1h.png"></p>
<p><strong>Figure 3-15: Time Profile Analysis</strong></p>
<p><br><br></p>
<p><a id="figure-3-16"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F14_time_profile_plot_Digoxin_Digoxin_iv__0_75_mg__1h.png"></p>
<p><strong>Figure 3-16: Time Profile Analysis 1</strong></p>
<p><br><br></p>
<p><a id="figure-3-17"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F15_time_profile_plot_Digoxin_Digoxin_iv__1_0_mg__0_5_h.png"></p>
<p><strong>Figure 3-17: Time Profile Analysis</strong></p>
<p><br><br></p>
<p><a id="figure-3-18"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F16_time_profile_plot_Digoxin_Digoxin_iv__1_0_mg__0_5_h.png"></p>
<p><strong>Figure 3-18: Time Profile Analysis 1</strong></p>
<p><br><br></p>
<p><a id="figure-3-19"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F17_time_profile_plot_Digoxin_Digoxin_iv__1_0_mg__1_h.png"></p>
<p><strong>Figure 3-19: Time Profile Analysis</strong></p>
<p><br><br></p>
<p><a id="figure-3-20"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F18_time_profile_plot_Digoxin_Digoxin_iv__1_0_mg__1_h.png"></p>
<p><strong>Figure 3-20: Time Profile Analysis 1</strong></p>
<p><br><br></p>
<p><a id="figure-3-21"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F19_time_profile_plot_Digoxin_Digoxin_iv__1_0_mg__Bolus.png"></p>
<p><strong>Figure 3-21: Time Profile Analysis</strong></p>
<p><br><br></p>
<p><a id="figure-3-22"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F20_time_profile_plot_Digoxin_Digoxin_iv__1_0_mg__Bolus.png"></p>
<p><strong>Figure 3-22: Time Profile Analysis 1</strong></p>
<p><br><br></p>
<p><a id="figure-3-23"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F21_time_profile_plot_Digoxin_Digoxin_iv__1_5_mg__1_h.png"></p>
<p><strong>Figure 3-23: Time Profile Analysis</strong></p>
<p><br><br></p>
<p><a id="figure-3-24"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F22_time_profile_plot_Digoxin_Digoxin_iv__1_5_mg__1_h.png"></p>
<p><strong>Figure 3-24: Time Profile Analysis 1</strong></p>
<p><br><br></p>
<p><a id="figure-3-25"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F23_time_profile_plot_Digoxin_Digoxin_po__0_25_mg.png"></p>
<p><strong>Figure 3-25: Time Profile Analysis</strong></p>
<p><br><br></p>
<p><a id="figure-3-26"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F24_time_profile_plot_Digoxin_Digoxin_po__0_25_mg.png"></p>
<p><strong>Figure 3-26: Time Profile Analysis 1</strong></p>
<p><br><br></p>
<p><a id="figure-3-27"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F25_time_profile_plot_Digoxin_Digoxin_po__0_4_mg.png"></p>
<p><strong>Figure 3-27: Time Profile Analysis</strong></p>
<p><br><br></p>
<p><a id="figure-3-28"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F26_time_profile_plot_Digoxin_Digoxin_po__0_4_mg.png"></p>
<p><strong>Figure 3-28: Time Profile Analysis 1</strong></p>
<p><br><br></p>
<p><a id="figure-3-29"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F27_time_profile_plot_Digoxin_Digoxin_po__0_5_mg.png"></p>
<p><strong>Figure 3-29: Time Profile Analysis</strong></p>
<p><br><br></p>
<p><a id="figure-3-30"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F28_time_profile_plot_Digoxin_Digoxin_po__0_5_mg.png"></p>
<p><strong>Figure 3-30: Time Profile Analysis 1</strong></p>
<p><br><br></p>
<p><a id="figure-3-31"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F29_time_profile_plot_Digoxin_Digoxin_po__0_6_mg.png"></p>
<p><strong>Figure 3-31: Time Profile Analysis</strong></p>
<p><br><br></p>
<p><a id="figure-3-32"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F30_time_profile_plot_Digoxin_Digoxin_po__0_6_mg.png"></p>
<p><strong>Figure 3-32: Time Profile Analysis 1</strong></p>
<p><br><br></p>
<p><a id="figure-3-33"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F31_time_profile_plot_Digoxin_Digoxin_po__0_75_mg.png"></p>
<p><strong>Figure 3-33: Time Profile Analysis</strong></p>
<p><br><br></p>
<p><a id="figure-3-34"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F32_time_profile_plot_Digoxin_Digoxin_po__0_75_mg.png"></p>
<p><strong>Figure 3-34: Time Profile Analysis 1</strong></p>
<p><br><br></p>
<p><a id="figure-3-35"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F33_time_profile_plot_Digoxin_Digoxin_po__1_0_mg.png"></p>
<p><strong>Figure 3-35: Time Profile Analysis</strong></p>
<p><br><br></p>
<p><a id="figure-3-36"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F34_time_profile_plot_Digoxin_Digoxin_po__1_0_mg.png"></p>
<p><strong>Figure 3-36: Time Profile Analysis 1</strong></p>
<p><br><br></p>
<p><a id="figure-3-37"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F35_time_profile_plot_Digoxin_Digoxin_po_MD__0_125_mg.png"></p>
<p><strong>Figure 3-37: Time Profile Analysis</strong></p>
<p><br><br></p>
<p><a id="figure-3-38"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F36_time_profile_plot_Digoxin_Digoxin_po_MD__0_125_mg.png"></p>
<p><strong>Figure 3-38: Time Profile Analysis 1</strong></p>
<p><br><br></p>
<p><a id="figure-3-39"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F37_time_profile_plot_Digoxin_Digoxin_po_MD__0_25_mg.png"></p>
<p><strong>Figure 3-39: Time Profile Analysis</strong></p>
<p><br><br></p>
<p><a id="figure-3-40"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F38_time_profile_plot_Digoxin_Digoxin_po_MD__0_25_mg.png"></p>
<p><strong>Figure 3-40: Time Profile Analysis 1</strong></p>
<p><br><br></p>
<p><a id="figure-3-41"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F39_time_profile_plot_Digoxin_Digoxin_po_MD__0_25_mg__LD.png"></p>
<p><strong>Figure 3-41: Time Profile Analysis</strong></p>
<p><br><br></p>
<p><a id="figure-3-42"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F40_time_profile_plot_Digoxin_Digoxin_po_MD__0_25_mg__LD.png"></p>
<p><strong>Figure 3-42: Time Profile Analysis 1</strong></p>
<p><br><br></p>
<p><a id="figure-3-43"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F41_time_profile_plot_Digoxin_Digoxin_po_MD__2x_0_25_mg.png"></p>
<p><strong>Figure 3-43: Time Profile Analysis</strong></p>
<p><br><br></p>
<p><a id="figure-3-44"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F42_time_profile_plot_Digoxin_Digoxin_po_MD__2x_0_25_mg.png"></p>
<p><strong>Figure 3-44: Time Profile Analysis 1</strong></p>
<p><br><br></p>
<p><a id="figure-3-45"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F43_time_profile_plot_Digoxin_Digoxin_po_MD__2x_0_25_mg___2.png"></p>
<p><strong>Figure 3-45: Time Profile Analysis</strong></p>
<p><br><br></p>
<p><a id="figure-3-46"></a></p>
<p><img src="images%2F006_section_results-and-discussion%2F009_section_ct-profiles-model-building%2F44_time_profile_plot_Digoxin_Digoxin_po_MD__2x_0_25_mg___2.png"></p>
<p><strong>Figure 3-46: Time Profile Analysis 1</strong></p>
<p><br><br></p>
</div>
</div>
<div class="section level2">
<h2 id="conclusion">4 Conclusion<a id="conclusion"></a><a class="anchor" aria-label="anchor" href="#conclusion"></a>
</h2>
<p>The final digoxin PBPK model applies elimination mainly via GFR and
P-gp and adequately describes the pharmacokinetics of digoxin in adults
receiving intravenous, and oral SD and MD of digoxin ranging from 0.125
to 1.5 mg, for different types of tablet formulations that were
described using a single formulation.</p>
<p>This model could be applied for the investigation of drug-drug
interactions (DDI), and translation to special populations such as
pediatrics with regard to P-gp based elimination.</p>
</div>
<div class="section level2">
<h2 id="references">5 References<a id="references"></a><a class="anchor" aria-label="anchor" href="#references"></a>
</h2>
<p><strong>Alsenz 2007</strong> Alsenz, J., Meister, E. &amp; Haenel, E.
Development of a partially automated solubility screening (PASS) assay
for early drug development. J. Pharm. Sci. 96, 1748â€“62 (2007).</p>
<p><strong>Atkinson 1988</strong> Atkinson, H.C. &amp; Begg, E.J.
Relationship between human milk lipid-ultrafiltrate and octanolwater
partition coefficients. J. Pharm. Sci. 77, 796â€“8 (1988).</p>
<p><strong>Bauer 2008</strong> Bauer, L.A. Applied Clinical
Pharmacokinetics. (2008).</p>
<p><strong>Becquemont 2001</strong> Becquemont, L. et al.Â Effect of
grapefruit juice on digoxin pharmacokinetics in humans. Clin. Pharmacol.
Ther. 70, 311â€“6 (2001).</p>
<p><strong>Caldwell 1976</strong> Caldwell, J.H. &amp; Cline, C.T.
Biliary excretion of digoxin in man. Clin. Pharmacol. Ther. 19, 410â€“5
(1976).</p>
<p><strong>Collett 2004</strong> Collett, A., Tanianis-Hughes, J.,
Hallifax, D. &amp; Warhurst, G. Predicting P-glycoprotein effects on
oral absorption: correlation of transport in Caco-2 with drug
pharmacokinetics in wildtype and mdr1a(-/-) mice in vivo. Pharm. Res.
21, 819â€“26 (2004).</p>
<p><strong>Ding 2004</strong> Ding, R. et al.Â Substantial
pharmacokinetic interaction between digoxin and ritonavir in healthy
volunteers. Clin. Pharmacol. Ther. 76, 73â€“84 (2004).</p>
<p><strong>Drugbank.ca</strong> (<a href="https://go.drugbank.com/drugs/DB00390" class="external-link uri">https://go.drugbank.com/drugs/DB00390</a>)</p>
<p><strong>Eckermann 2012</strong> Eckermann, G., Lahu, G., Nassr, N.
&amp; Bethke, T.D. Absence of pharmacokinetic interaction between
roflumilast and digoxin in healthy adults. J. Clin. Pharmacol. 52, 251â€“7
(2012).</p>
<p><strong>Friedrich 2011</strong> Friedrich, C. et al.Â Evaluation of
the pharmacokinetic interaction after multiple oral doses of linagliptin
and digoxin in healthy volunteers. Eur. J. Drug Metab. Pharmacokinet.
36, 17â€“24 (2011).</p>
<p><strong>Greiner 1999</strong> Greiner, B. et al.Â The role of
intestinal P-glycoprotein in the interaction of digoxin and rifampin. J.
Clin. Invest. 104, 147â€“53 (1999).</p>
<p><strong>Gurley 2008b</strong> Gurley, B.J., Swain, A., Williams,
D.K., Barone, G. &amp; Battu, S.K. Gauging the clinical significance of
P-glycoprotein-mediated herb-drug interactions: comparative effects of
St.Â Johnâ€™s wort, Echinacea, clarithromycin, and rifampin on digoxin
pharmacokinetics. Mol. Nutr. food Res. 52, 772â€“9 (2008).</p>
<p><strong>Hanke 2018</strong> Hanke N, Frechen S, Moj D, Britz H,
Eissing T, Wendl T, Lehr T. PBPK Models for CYP3A4 and P-gp DDI
Prediction: A Modeling Network of Rifampicin, Itraconazole,
Clarithromycin, Midazolam, Alfentanil, and Digoxin. CPT Pharmacometrics
Syst Pharmacol.. 2018 Oct;7(10):647-659.</p>
<p><strong>Hayward 1978</strong> Hayward, R.P., Greenwood, H. &amp;
Hamer, J. Comparison of digoxin and medigoxin in normal subjects. Br. J.
Clin. Pharmacol. 6, 81â€“6 (1978).</p>
<p><strong>Hinderling 1984</strong> Hinderling, P.H. Kinetics of
partitioning and binding of digoxin and its analogues in the
subcompartments of blood. J. Pharm. Sci. 73, 1042â€“53 (1984).</p>
<p><strong>Jalava 1997</strong> Jalava, K.M., Partanen, J. &amp;
Neuvonen, P.J. Itraconazole decreases renal clearance of digoxin. Ther.
Drug Monit. 19, 609â€“13 (1997).</p>
<p><strong>Johne 1999</strong> Johne, A. et al.Â Pharmacokinetic
interaction of digoxin with an herbal extract from St Johnâ€™s wort
(Hypericum perforatum). Clin. Pharmacol. Ther. 66, 338â€“45 (1999).</p>
<p><strong>Katz 2010</strong> Katz, A. et al.Â Selectivity of digitalis
glycosides for isoforms of human Na,K-ATPase. J. Biol. Chem. 285,
19582â€“92 (2010).</p>
<p><strong>Kirch 1986</strong> Kirch, W., Hutt, H.J., Dylewicz, P.,
GrÃ¤f, K.J. &amp; Ohnhaus, E.E. Dose-dependence of the nifedipine-digoxin
interaction? Clin. Pharmacol. Ther. 39, 35â€“9 (1986).</p>
<p><strong>Koup 1975</strong> Koup, J.R., Greenblatt, D.J., Jusko, W.J.,
Smith, T.W. &amp; Koch-Weser, J. Pharmacokinetics of digoxin in normal
subjects after intravenous bolus and infusion doses. J. Pharmacokinet.
Biopharm. 3, 181â€“92 (1975).</p>
<p><strong>Kramer 1979</strong> Kramer, W.G. et al.Â Pharmacokinetics of
digoxin: relationship between response intensity and predicted
compartmental drug levels in man. J. Pharmacokinet. Biopharm. 7, 47â€“61
(1979).</p>
<p><strong>Kuepfer 2016</strong> Kuepfer L, Niederalt C, Wendl T,
Schlender JF, Willmann S, Lippert J, Block M, Eissing T, Teutonico D.
Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model.CPT
Pharmacometrics Syst Pharmacol. 2016 Oct;5(10):516-531. doi:
10.1002/psp4.12134. Epub 2016 Oct 19.</p>
<p><strong>Lalonde 1985</strong> Lalonde, R.L., Deshpande, R., Hamilton,
P.P., McLean, W.M. &amp; Greenway, D.C. Acceleration of digoxin
clearance by activated charcoal. Clin. Pharmacol. Ther. 37, 367â€“71
(1985).</p>
<p><strong>Larsen 2007</strong> Larsen, U.L. et al.Â Human intestinal
P-glycoprotein activity estimated by the model substrate digoxin. Scand.
J. Clin. Lab. Invest. 67, 123â€“34 (2007).</p>
<p><strong>Martin 1997</strong> Martin, D.E. et al.Â Lack of effect of
eprosartan on the single dose pharmacokinetics of orally administered
digoxin in healthy male volunteers. Br. J. Clin. Pharmacol. 43, 661â€“4
(1997).</p>
<p><strong>Neuhoff 2013</strong> Neuhoff, S. et al.Â Application of
permeability-limited physiologically-based pharmacokinetic models: part
I-digoxin pharmacokinetics incorporating P-glycoprotein-mediated efflux.
J. Pharm. Sci. 102, 3145â€“60 (2013).</p>
<p><strong>Nishimura 2005</strong> Nishimura, M. &amp; Naito, S.
Tissue-specific mRNA expression profiles of human ATP-binding cassette
and solute carrier transporter superfamilies. Drug Metab. Pharmacokinet.
20, 452â€“77 (2005).</p>
<p><strong>Obach 2008</strong> Obach, R.S., Lombardo, F. &amp; Waters,
N.J. Trend analysis of a database of intravenous pharmacokinetic
parameters in humans for 670 drug compounds. Drug Metab. Dispos. 36,
1385â€“405 (2008).</p>
<p><strong>Ochs 1975</strong> Ochs, H., Bodem, G., SchÃ¤fer, P.K.,
Kodrat, G., Dengler, H.J. Absorption of digoxin from the distal parts of
the intestine in man. Eur J Clin Pharmacol. 1975 Dec 19;9(2-3):95-7.</p>
<p><strong>Ochs 1978</strong> Ochs, H.R., Greenblatt, D.J., Bodem, G.
&amp; Harmatz, J.S. Dose-independent pharmacokinetics of digoxin in
humans. Am. Heart J. 96, 507â€“11 (1978).</p>
<p><strong>Oosterhuis 1991</strong> Oosterhuis, B., Jonkman, J.H.,
Andersson, T., Zuiderwijk, P.B. &amp; Jedema, J.N. Minor effect of
multiple dose omeprazole on the pharmacokinetics of digoxin after a
single oral dose. Br. J. Clin. Pharmacol. 32, 569â€“72 (1991).</p>
<p><strong>PK-Sim Ontogeny Database Version 7.3</strong> (<a href="https://github.com/Open-Systems-Pharmacology/OSPSuite.Documentation/blob/38cf71b384cfc25cfa0ce4d2f3addfd32757e13b/PK-Sim%20Ontogeny%20Database%20Version%207.3.pdf" class="external-link uri">https://github.com/Open-Systems-Pharmacology/OSPSuite.Documentation/blob/38cf71b384cfc25cfa0ce4d2f3addfd32757e13b/PK-Sim%20Ontogeny%20Database%20Version%207.3.pdf</a>)</p>
<p><strong>Prasad 2014</strong> Prasad, B. et al.Â Interindividual
variability in hepatic organic anion-transporting polypeptides and
P-glycoprotein (ABCB1) protein expression: quantification by liquid
chromatography tandem mass spectroscopy and influence of genotype, age,
and sex. Drug Metab. Dispos. 42, 78â€“88 (2014).</p>
<p><strong>Qiu 2010</strong> Qiu, R. et al.Â Lack of a pharmacokinetic
interaction between dimebon (latrepirdine) and digoxin in healthy
subjects. Am. Soc. Clin. Pharmacol. Ther. Meet. Atlanta, GA, USA
(2010).</p>
<p><strong>Ragueneau 1999</strong> Ragueneau, I. et al.Â Pharmacokinetic
and pharmacodynamic drug interactions between digoxin and macrogol 4000,
a laxative polymer, in healthy volunteers. Br. J. Clin. Pharmacol. 48,
453â€“6 (1999).</p>
<p><strong>Rengelshausen 2003</strong> Rengelshausen, J. et
al.Â Contribution of increased oral bioavailability and reduced
nonglomerular renal clearance of digoxin to the digoxin-clarithromycin
interaction. Br. J. Clin. Pharmacol. 56, 32â€“8 (2003).</p>
<p><strong>Rodin 1988</strong> Rodin, S.M., Johnson, B.F., Wilson, J.,
Ritchie, P. &amp; Johnson, J. Comparative effects of verapamil and
isradipine on steady-state digoxin kinetics. Clin. Pharmacol. Ther. 43,
668â€“72 (1988).</p>
<p><strong>Schlender 2016</strong> Schlender JF, Meyer M, Thelen K,
Krauss M, Willmann S, Eissing T, Jaehde U. Development of a Whole-Body
Physiologically Based Pharmacokinetic Approach to Assess the
Pharmacokinetics of Drugs in Elderly Individuals. Clin Pharmacokinet.
2016 Dec;55(12):1573-1589.</p>
<p><strong>Steiness 1982</strong> Steiness, E., Waldorff, S. &amp;
Hansen, P.B. Renal digoxin clearance: dependence on plasma digoxin and
diuresis. Eur. J. Clin. Pharmacol. 23, 151â€“4 (1982).</p>
<p><strong>Stephens 2001</strong> Stephens R.H., Oâ€™Neill C.A., Warhurst
A., Carlson G.L., Rowland M-, Warhurst G. Kinetic profiling of
P-glycoprotein-mediated drug efflux in rat and human intestinal
epithelia. J. Pharmacol Exp Ther. 2001 Feb;296(2):584-91.</p>
<p><strong>Tayrouz 2003</strong> Tayrouz, Y. et al.Â Pharmacokinetic and
pharmaceutic interaction between digoxin and Cremophor RH40. Clin.
Pharmacol. Ther. 73, 397â€“405 (2003).</p>
<p><strong>Troutman 2003</strong> Troutman, M.D.Â &amp; Thakker, D.R.
Efflux ratio cannot assess P-glycoprotein-mediated attenuation of
absorptive transport: asymmetric effect of P-glycoprotein on absorptive
and secretory transport across Caco-2 cell monolayers. Pharm. Res. 20,
1200â€“9 (2003).</p>
<p><strong>Tsutsumi 2002</strong> Tsutsumi, K. et al.Â The effect of
erythromycin and clarithromycin on the pharmacokinetics of intravenous
digoxin in healthy volunteers. J. Clin. Pharmacol. 42, 1159â€“64
(2002).</p>
<p><strong>Vaidyanathan 2008</strong> Vaidyanathan, S. et
al.Â Pharmacokinetics of the oral direct renin inhibitor aliskiren in
combination with digoxin, atorvastatin, and ketoconazole in healthy
subjects: the role of P-glycoprotein in the disposition of aliskiren. J.
Clin. Pharmacol. 48, 1323â€“38 (2008).</p>
<p><strong>Verstuyft 2003</strong> Verstuyft, C. et al.Â Dipyridamole
enhances digoxin bioavailability via P-glycoprotein inhibition. Clin.
Pharmacol. Ther. 73, 51â€“60 (2003).</p>
<p><strong>Wagner 1981</strong> Wagner, J.G., Popat, K.D., Das, S.K.,
Sakmar, E. &amp; Movahhed, H. Evidence of nonlinearity in digoxin
pharmacokinetics. J. Pharmacokinet. Biopharm. 9, 147â€“66 (1981).</p>
<p><strong>Westphal 2000</strong> Westphal, K. et al.Â Oral
bioavailability of digoxin is enhanced by talinolol: evidence for
involvement of intestinal P-glycoprotein. Clin. Pharmacol. Ther. 68,
6â€“12 (2000).</p>
</div>
  </main><aside class="col-md-3"><nav id="toc" aria-label="Table of contents"><h2>On this page</h2>
    </nav></aside>
</div>



    <footer><div class="pkgdown-footer-left">
  <p>Developed by Pierre Chelle.</p>
</div>

<div class="pkgdown-footer-right">
  <p>Site built with <a href="https://pkgdown.r-lib.org/" class="external-link">pkgdown</a> 2.1.1.</p>
</div>

    </footer>
</div>





  </body>
</html>
